Skip to search formSkip to main contentSkip to account menu

E5564

Known as: E 5564, E-5564 
National Institutes of Health

Related topics

Related topics

5 relations
B 1287analogs & derivativeseritoran

Broader (2)

Eritoran TetrasodiumLipid A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma.
2012
2012
A Synthetic Lipid A Mimetic Modulates Human TLR4 Activity
Innate immunity recognition relies on a diverse set of germ line encoded receptors, termed pattern recognition receptors (PRR… 
2012
2012
Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins
Lipid A, the active moiety of LPS, exerts its effects through interaction with TLR4, triggering a signalling cascade that results… 
Review
2011
Review
2011
Peptide-based treatment of sepsis
Sepsis (blood poisoning) is a severe infectious disease with high mortality, and no effective therapy is actually known. In the… 
2011
2011
In Vivo Toll-Like Receptor 4 Antagonism Restores Cardiac Function During Endotoxemia
ABSTRACT Severe sepsis and septic shock are often accompanied by acute cardiovascular depression. Lipopolysaccharide (LPS… 
Review
2010
Review
2010
Tele-intensive care unit: the horse out of the barn.
Despite the decline in total hospital beds, the intensive care unit (ICU) beds increased from 1985 to 2000 in the United States… 
Highly Cited
2006
Highly Cited
2006
E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes
Abstract.Objective and designIn this ex vivo laboratory study, we investigated the effects of E5564 (eritoran), a toll-like… 
Review
2004
Review
2004
Drug evaluation: E-5564.
Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological… 
Highly Cited
2001
Highly Cited
2001
Membrane-Associated Proteins of a Lipopolysaccharide-Deficient Mutant of Neisseria meningitidis Activate the Inflammatory Response through Toll-Like Receptor 2
ABSTRACT The recent isolation of a lipopolysaccharide (LPS)-deficient mutant of Neisseria meningitidis has allowed us to explore… 
Highly Cited
2001
Highly Cited
2001
A Novel Synthetic Acyclic Lipid A-like Agonist Activates Cells via the Lipopolysaccharide/Toll-like Receptor 4 Signaling Pathway*
ER-112022 is a novel acyclic synthetic lipid A analog that contains six symmetrically organized fatty acids on a noncarbohydrate… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)